American Vanguard Corp: Form 10-Q for the period ended Mar 31, 2019
Filed with the SEC on May 8, 2019 and accepted by EDGAR at May 8, 2019, 16:01 ET.
Management's discussion and analysis
As filed, 23,834 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
FORWARD-LOOKING STATEMENTS/RISK FACTORS:
The Company, from time-to-time, may discuss forward-looking statements including assumptions concerning the Company’s operations, future results and prospects. These forward-looking statements are based on current expectations and are subject to a number of risks, uncertainties and other factors. In connection with the Private Securities Litigation Reform Act of 1995, the Company provides the following cautionary statements identifying important factors which, among other things, could cause the actual results and events to differ materially from those set forth in or implied by the forward-looking statements and related assumptions contained in the entire Report. Such factors include, but are not limited to: product demand and market acceptance risks; the effect of economic conditions; weather conditions; changes in regulatory policy; the impact of competitive products and pricing; changes in foreign exchange rates; product development and commercialization difficulties; capacity and supply constraints or difficulties; availability of capital resources; general business regulations, including taxes and other risks as detailed from time-to-time in the Company’s reports and filings filed with the U.S. Securities and Exchange Commission (the “SEC”). It is not possible to foresee or identify all such factors. For more detailed information, refer to Item 1A., Risk factors and Item 7A., Quantitative and Qualitative Disclosures about Market Risk, in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018.
MANAGEMENT OVERVIEW
The Company’s overall operating results the first three months of 2019 were, for the most part, below those of the same period of 2018. Net sales were down about 4% ($99,676 compared to $104,108) and gross profit was down less than 1% ($41,702 v. $41,051). Gross margin rose to 42% from 39% of net sales, and operating expenses rose by approximately 3% ($34,800 v. $33,700). Net income was down about 16% ($3,906 v. $4,655)
Broadly speaking, the Company’s domestic crop and non-crop businesses were adversely affected by weather in many regions – flooding in the Midwest, freezing and wet conditions in the Pacific Northwest and recurrent rain in the South. By contrast, with improved sales in LATAM and the addition of our newly acquired business in Brazil, our international business recorded higher sales and gross profit during the period. Gross profit margins on a consolidated basis were higher than those of the comparable period in 2018. Further, factory activity was strong, and as a result, factory underabsorption expense reduced during the quarter. Despite those accretive factors, however, the drop in domestic sales, coupled with increased operating expenses (due largely to the build-out of our international businesses) and increased interest expense (arising from higher borrowing during the period), yielded lower net income.
| Net sales: | For the three months ended March 31, 2019 | 2018 | Change | % Change |
|---|---|---|---|---|
| US crop | $50,270 | $57,344 | $(7,074) | -12% |
| US non-crop | 11,267 | 11,892 | (625) | -5% |
| US total | 61,537 | 69,236 | (7,699) | -11% |
| International | 38,139 | 34,872 | 3,267 | 9% |
| Net sales: | $99,676 | $104,108 | $(4,432) | -4% |
| Gross profit: | ||||
| US crop | $23,822 | $25,060 | $(1,238) | -4% |
| US non-crop | 5,846 | 5,812 | 34 | -16% |
| US total | 29,668 | 30,872 | (1,204) | -6% |
| International | 12,034 | 10,179 | 1,855 | 17% |
| Total gross profit: | $41,702 | $41,051 | $651 | -1% |
| Gross margin domestic | 48% | 45% | ||
| Gross margin international | 32% | 29% | ||
| Gross margin total | 42% | 39% |
19
Our domestic crop business recorded net sales that were about 12% below those of first quarter 2018 ($50,270 v. $57,344). Granular soil insecticides, including Counter and Thimet, declined largely due to wet conditions in the Southeast. Similarly, rain and snow in multiple regions prevented the normal application of our soil fumigants; some of these applications can be made in the second quarter, while others may be pushed out into the fall. Sales of our herbicide, Dacthal, which is used on high-value vegetable crops, was also affected by wet weather. By contrast, in spite of weather challenges, Impact sales were up year-over-year, in light of low channel inventory at the end of 2018 and the popularity of our multi-product program promotion. Wet conditions also affected demand for Abba, particularly in the nut tree market, and Parazone in the South, as a burn-down herbicide.
Similarly, our domestic non-crop business showed decreased net sales (down about 5% to $11,267 from $11,892) quarter-over-quarter. This result was due largely to decreased sales of our mosquito adulticide, Dibrom. In conjunction with extreme hurricane activity in 2017, we sold record amounts of Dibrom, followed by above-normal restocking in 2018, and more normalized levels in the first quarter of 2019. As a partial offset to this decline, sales of pest strips increased as did those of our pharmaceutical products. Within our nursery and ornamental business, we experienced sluggish demand for homeowner garden and landscape products due to wet weather, which was offset in part by increased fungicide sales.
Net sales of our international businesses were up by about 9% during the period ($38,139 v. $34,872). A significant part of this gain was due to the addition of sales from our newly-acquired Brazilian subsidiaries, Agrovant and Defensive, which were led by Argenfrut, a mineral oil-based insecticide used primarily on citrus, and Red Shield, a copper-based foliar insecticide used on multiple crops. In addition, we experienced increased sales from AgriCenter in Central America, led by mineral oil products for fungicidal control in banana plants, chlorothalonil for use on black sigatoka in Costa Rica, special nutrition products from Greenplant, and soil amendments and biorational fungicides. Partially offsetting these increases were decreased sales of various products into the pineapple market, due largely to reduced insect pressure, and insecticides due to dry El Nino conditions within the region. Sales of both Mocap and Nemacur were impacted by crop inputs rotation decisions, which resulted in lower sales than in prior year.
RESULTS OF OPERATIONS
Quarter Ended March 31:
| Net sales: | 2019 | 2018 | Change | % Change |
|---|---|---|---|---|
| Insecticides | $40,183 | $46,158 | $(5,975) | -13% |
| Herbicides/soil fumigants/fungicides | 31,535 | 36,515 | (4,980) | -14% |
| Other, including plant growth regulators and distribution | 15,670 | 8,645 | 7,025 | 81% |
| Total crop | 87,388 | 91,318 | (3,930) | -4% |
| Non-crop, including distribution | 12,288 | 12,790 | (502) | -4% |
| Net sales: | $99,676 | $104,108 | $(4,432) | -4% |
| Cost of sales: | ||||
| Insecticides | $22,955 | $28,941 | $(5,986) | -21% |
| Herbicides/soil fumigants/fungicides | 18,872 | 22,229 | (3,357) | -15% |
| Other, including plant growth regulators and distribution | 10,205 | 5,177 | 5,028 | 97% |
| Total crop | 52,032 | 56,347 | (4,315) | -8% |
| Non-crop including distribution | 5,942 | 6,710 | (768) | -11% |
| Total cost of sales: | $57,974 | $63,057 | $(5,083) | -8% |
| Gross profit: | ||||
| Insecticides | $17,228 | $17,217 | $11 | 0% |
| Herbicides/soil fumigants/fungicides | 12,663 | 14,286 | (1,623) | -11% |
| Other, including plant growth regulators and distribution | 5,465 | 3,468 | 1,997 | 58% |
| Gross profit crop | 35,356 | 34,971 | 385 | 1% |
| Gross profit non-crop including distribution | 6,346 | 6,080 | 266 | 4% |
| Total gross profit: | $41,702 | $41,051 | $651 | 2% |
| Gross margin crop | 40% | 38% | ||
| Gross margin non-crop | 52% | 48% | ||
| Total gross margin | 42% | 39% |
20
On a consolidated basis, net sales of insecticides were down approximately 13% to end at $40,183, as compared to $46,158 during the first quarter of 2018. This includes reduced sales of our granular soil insecticides, as described above, as well as those of Mocap® and Nemacur®. First quarter net sales of our cotton insecticide Bidrin® increased as compared to the same period of the prior year, primarily due to lower than average channel inventory levels and an expectation for increased cotton plantings in the Southeast US region.
Within the group of herbicides/fungicides/fumigants used in crop applications, net sales for the first quarter of 2019 decreased by approximately 14% to $31,535 from $36,515 in the comparable period of 2018. Net sales of our herbicide products decreased by 13%, driven by softer demand for our Dacthal and Parazone products, partially offset by steady performance from our existing Impact and Hyvar/Krovar products plus incremental sales of our newly-acquired Assure II herbicide. Our soil fumigants business declined by approximately 13% from the prior year’s first quarter, while year-over-year our fungicide sales decreased 27% primarily due to elevated levels of channel inventory at the start of the 2018-19 growing season.
Within the group of other products (which includes certain AgriCenter products, the Agrovant/Defensive Brazilian operation, plant growth regulators, molluscicides and tolling activity), net sales increased by 81% to $15,670 from $8,645 during the first quarter of 2018. Most of this increase arose from our newly acquired businesses Agrovant and Defensive in Brazil and higher quarterly sales of our growth regulator product NAA.
Our non-crop sales ended the first quarter of 2019 down 4% at $12,288, as compared to $12,790 for the same period of the prior year. As noted above, the main driver was a reduction in sales of our aerial-applied mosquito adulticide Dibrom, partially offset by strong Pest Strip sales.
Our cost of sales for the first quarter of 2019 ended at $57,974 or 58% of net sales. This compares to $63,057 or 61% of net sales in the same period of 2018. Margins improved for both our domestic and our international businesses and included a reduction in sales of lower margin products in our domestic markets
Gross profit for the first quarter of 2019 was approximately flat as compared to the same period of the prior year and ended at $41,702, as compared to $41,051 for the first quarter of 2018. The change in mix described above had the impact of improving gross margin percentage by approximately 2% and included an overall improvement in our factory performance. Gross margin percentage ended at 42% in the first quarter of 2019, as compared to 39% in the first quarter of the prior year.
Operating expenses increased by $1,100 or 3% to $34,800 for the three months ended March 31, 2019, as compared to the same period in 2018. The differences in operating expenses by department are as follows:
| 2019 | 2018 | Change | % Change | |
|---|---|---|---|---|
| Selling | $11,038 | $9,481 | $1,557 | 16% |
| General and administrative | 11,180 | 11,164 | 16 | 0% |
| Research, product development and regulatory | 5,683 | 6,277 | (594) | -9% |
| Freight, delivery and warehousing | 6,899 | 6,778 | 121 | 2% |
| $34,800 | $33,700 | $1,100 | 3% |
- Selling expenses increased by $1,557 to end at $11,038 for the three months ended March 31, 2019, as compared to the same period of 2018. The main driver was an increase in activities from the newly acquired businesses, the impact of exchange rate changes in our Central and South American businesses and increased spending on advertising for our expanding business.
- General and administrative expenses remained flat to end at $11,180 for the three months ended March 31, 2019, as compared to the same period of 2018. This includes reserves in the amount of $950 related to doubtful accounts receivables for our Central and South American businesses, and expenses associated with the businesses acquired in the final quarter of 2018 and the first quarter of 2019. Those costs were offset by an adjustment made on a revised estimate of our deferred compensation in the amount of $1,543 related to businesses acquired in 2017. Finally, we recorded a decrease in incentive compensation as a result of business performance.
- Research, product development costs and regulatory expenses decreased by $594 to end at $5,683 for the three months ended March 31, 2019, as compared to the same period of 2018. The main drivers were decreases in our product defense and product development costs.
- Freight, delivery and warehousing costs for the three months ended March 31, 2019 were $6,899 or 6.9% of sales as compared to $6,778 or 6.5% of sales for the same period in 2018. This change is primarily driven by mix of product shipped and associated delivery destinations during the period.
Interest costs net of capitalized interest were $1,612 in the first three months of 2019, as compared to $837 in the same period of 2018. Interest costs are summarized in the following table:
Average Indebtedness and Interest expense
| Q1 2019 Average Debt | Interest Expense | Interest Rate | Q1 2018 Average Debt | Interest Expense | Interest Rate | |
|---|---|---|---|---|---|---|
| Revolving line of credit (average) | $143,144 | $1,576 | 4.4% | $88,898 | $699 | 3.1% |
| Amortization of deferred loan fees | — | 50 | — | — | 59 | — |
| Amortization of other deferred liabilities | — | — | — | — | 102 | — |
| Other interest (income) expense | — | 13 | — | — | (6) | — |
| Subtotal | $143,144 | $1,639 | 4.6% | $88,898 | $854 | 3.8% |
| Capitalized interest | — | (27) | — | — | (17) | — |
| Total | $143,144 | $1,612 | 4.5% | $88,898 | $837 | 3.8% |
The Company’s average overall debt for the three months ended March 31, 2019 was $143,144, as compared to $88,898 for the three months ended March 31, 2018. Our borrowings in the three months ended March 31, 2019 were higher than the same period of the prior year primarily driven by the acquisitions completed in the last quarter of 2018 and first quarter of 2019 and the associated investment in expanded working capital. As can be seen from the table above, our effective bank interest rate on our revolving line of credit was 4.4% for the three months ended March 31, 2019, as compared to 3.1% in 2018.
Income tax expense decreased by $332 to end at an expense of $1,360 for the three months ended March 31, 2019, as compared to $1,692 for the comparable period in 2018. The effective tax rate for the quarter was 25.7%, as compared to 26.0% in the same period of the prior year. The effective tax rate for all interim periods is based on the projected income for the full year and is subject to ongoing review and adjustment by management.
During the three months ended March 31, 2019 and 2018 we recognized a loss of $24 and $121, respectively, on our investment in the Hong Kong joint venture which is a 50% owned equity investment. During the three months ended March 31, 2018, we recognized a loss of $96 on our investment in TyraTech. TyraTech became a wholly owned and consolidated subsidiary on November 9, 2018.
Non-controlling interest represents the share of net income or loss that is attributable to the minority stockholder of our majority owned subsidiary, Envance. During the three months ended March 31, 2018 non-controlling interest amounted to a gain of $50. Envance became a wholly owned subsidiary on November 9, 2018.
Our overall net income for the first three months of 2019 was $3,906 or $0.13 per basic and diluted share, as compared to $4,655 or $0.16 per basic and diluted share in the same quarter of 2018.
LIQUIDITY AND CAPITAL RESOURCES
The Company used cash of $20,263 in operating activities during the three months ended March 31, 2019, as compared to $9,235 during the three months ended March 31, 2018. Included in the $20,263 are net income of $3,906, plus non-cash depreciation, amortization of intangibles and other assets and discounted future liabilities, in the amount of $5,691. Provision for bad debts in the amount of $1,034 was offset by a revision of $1,543 made to deferred compensation associated with businesses acquired in 2017. Stock based compensation of $1,485 and losses from equity method investments of $24 provided net cash inflows of $9,855, as compared to $12,630 for the same period of 2018.
During the first three months of 2019, the Company increased working capital by $28,358, as compared to $26,629 during the same period of the prior year. Included in this change: inventories increased by $23,763 as part of the expanded businesses and the point in time in the 2018-19 growing season in the United States agricultural market. During the first quarter of 2018, our inventory increased by $19,558. Deferred revenue decreased by $16,036 as compared to $2,740 in the same period of 2018, driven by customer decisions regarding demand, payment timing and our cash incentive programs. Our accounts payable balances increased by $4,960, as compared to $9,613 in the same period of 2018, reflecting a faster start up to production activity this year and the impact of the newly acquired businesses. Accounts receivables decreased by $6,812, as compared to an increase of $9,554 in the same period of 2018. Prepaid expenses increased by $2,724 and income tax receivable decreased by $750. Accrued programs increased by $2,391, as compared to $4,634 in the prior year. The change reflected changed competitive pricing primarily related to certain products. Finally, other payables and accrued expenses decreased by $2,508 as compared to $3,201 in the prior year as a result of the incentive compensation accrual.
With regard to our program accrual, the reduction (as noted above) primarily reflects our mix of sales and customers in Q1 of 2019, as compared to the prior year. The Company accrues programs in line with the growing season upon which specific products are targeted. Typically crop products have a growing season that ends on September 30th of each year. During the first quarter of 2019, the Company made accruals for programs in the amount of $14,092 and made payments in the amount of $11,701. During the first quarter of prior year, the Company made accruals in the amount of $13,542 and made payments in the amount of $8,908.
Cash used for investing activities was $27,615 for the three months ended March 31, 2019, as compared to $2,368 in March 31, 2018. The Company spent $24,246 on business acquisition and $3,369 on fixed assets acquisitions primarily focused on continuing to invest in manufacturing infrastructure.
During the three months ended March 31, 2019, financing activities provided $48,865, principally from the borrowings on the Company’s senior credit facility as compared to $13,172 for the same period of the prior year. In the first quarter of 2019, we paid dividends to stockholders amounting to $581, as compared to $438 in the same period of 2018.
The Company has various loans in place that together constitute the long-term loan balances shown in the condensed consolidated balance sheets as at March 31, 2019 and December 31, 2018. These are summarized in the following table:
| Long-term indebtedness | March 31, 2019 | December 31, 2018 |
|---|---|---|
| Revolving line of credit | $150,000 | $97,400 |
| Deferred loan fees | (679) | (729) |
| Total indebtedness | $149,321 | $96,671 |
As of June 30, 2017, AMVAC Chemical Corporation (“AMVAC”), the Company’s principal operating subsidiary, as borrower, and affiliates (including the Company, AMVAC CV and AMVAC BV), as guarantors and/or borrowers, entered into a Third Amendment to Second Amended and Restated Credit Agreement (the “Credit Agreement”) with a group of commercial lenders led by Bank of the West as agent, swing line lender and Letter of Credit issuer. The Credit Agreement is a senior secured lending facility, consisting of a line of credit of up to $250,000, an accordion feature of up to $100,000 and a maturity date of June 30, 2022. The Credit Agreement contains two key financial covenants; namely, borrowers are required to maintain a Consolidated Funded Debt Ratio of no more than 3.25-to-1 and a Consolidated Fixed Charge Covenant Ratio of at least 1.25-to-1. The Company’s borrowing capacity varies with its financial performance, measured in terms of EBITDA as defined in the Credit Agreement, for the trailing twelve month period. Under the Credit Agreement, revolving loans bear interest at a variable rate based, at borrower’s election with proper notice, on either (i) LIBOR plus the “Applicable Rate” which is based upon the Consolidated Funded Debt Ratio (“Eurocurrency Rate Loan”) or (ii) the greater of (x) the Prime Rate, (y) the Federal Funds Rate plus 0.5%, and (z) the Daily One-Month LIBOR Rate plus 1.00%, plus, in the case of (x), (y) or (z) the Applicable Rate (“Alternate Base Rate Loan”). Interest payments for Eurocurrency Rate Loans are payable on the last day of each interest period (either one, two, three or six months, as selected by the borrower) and the maturity date, while interest payments for Alternate Base Rate Loans are payable on the last business day of each month and the maturity date.
At March 31, 2019, based on its performance against the most restrictive covenants listed above, the Company had the capacity to increase its borrowings by up to $56,707, according to the terms of the Credit Agreement. This compares to an available borrowing capacity of $124,936 as of March 31, 2018. The level of borrowing capacity is driven by three factors: (1) our financial performance, as measured in EBITDA for both the trailing twelve month period and proforma basis arising from acquisitions, which have improved, (2) net borrowings, which have increased and (3) the leverage covenant (being the number of times EBITDA the Company may borrow under its credit facility agreement.
We believe that anticipated cash flow from operations, existing cash balances and available borrowings under our senior credit facility will be sufficient to provide us with liquidity necessary to fund our working capital and cash requirements for the next twelve months.
RECENTLY ISSUED ACCOUNTING GUIDANCE
Please refer to Note 15 in the accompanying Notes to the Condensed Consolidated Financial Statements for recently issued and adopted accounting standards.
CRITICAL ACCOUNTING POLICIES AND ESTIMATES
The Company continually re-assesses the critical accounting policies used in preparing its financial statements. In the Company’s Form 10-K filed with the SEC for the year ended December 31, 2018, the Company provided a comprehensive statement of critical accounting policies. These policies have been reviewed in detail as part of the preparation work for this Form 10-Q. After our review of these matters, we have determined that, during the subject reporting period, there has been no material change to the critical accounting policies that are listed in the Company’s Form 10-K for the year ended December 31, 2018, except for the adoption of ASC 842, Leases, as of January 1, 2019.
Certain of the Company’s policies require the application of judgment by management in selecting the appropriate assumptions for calculating financial estimates. These judgments are based on historical experience, terms of existing contracts, commonly accepted industry practices and other assumptions that the Company believes are reasonable under the circumstances. These estimates and assumptions are reviewed periodically and the effects of revisions are reflected in the condensed consolidated financial statements in the period that revisions are determined to be necessary. Actual results may differ from these estimates under different outcomes or conditions.
Market risk
As filed, 1,252 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The Company is exposed to market risk related to changes in interest rates, primarily from its borrowing activities. The Company’s indebtedness to its primary lender is evidenced by a line of credit with a variable rate of interest, which fluctuates with changes in the lender’s reference rate. For more information, please refer to the applicable disclosures in the Company’s Form 10-K filed with the SEC for the year ended December 31, 2018.
The Company conducts business in various foreign currencies, primarily in Europe, Mexico, Central and South America. Therefore changes in the value of the currencies of such countries or regions affect the Company’s financial position and cash flows when translated into U.S. Dollars. The Company has mitigated and will continue to mitigate a portion of its currency exchange exposure through natural hedges based on the operation of decentralized foreign operating companies in which the majority of all costs are local-currency based. Furthermore, the Company has established a procedure for covering forward exchange rates on specific purchase orders when appropriate. A 10% change in the value of all foreign currencies would have an immaterial effect on the Company’s financial position and cash flows.
Controls and procedures
As filed, 1,229 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
As of March 31, 2019, the Company has a comprehensive set of disclosure controls and procedures designed to ensure that all information required to be disclosed in our filings under the Securities Exchange Act (1934) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. As of March 31, 2019, the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer, has concluded, based on their evaluation, that the Company’s disclosure controls and procedures are effective to provide reasonable assurance of the achievement of the objectives described above.
There were no changes in the Company’s internal controls over financial reporting that occurred during the most recent quarter that have materially affected, or are reasonably likely to materially affect, the Company’s internal controls over financial reporting. We implemented internal controls to ensure we adequately evaluated our contracts and properly assessed the impact of the new accounting standards under ASC 842, Leases.
PART II. OTHER INFORMATION
The Company was not required to report any matters or changes for any items of Part II except as disclosed below.
Risk factors
As filed, 407 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The Company continually re-assesses the business risks, and as part of that process detailed a range of risk factors in the disclosures in American Vanguard’s Report on Form 10-K for the fiscal year ended December 31, 2018, filed on March 12, 2019. In preparing this document, we have reviewed all the risk factors included in that document and find that there are no material changes to those risk factors.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2019-01-01 to 2019-03-31 | $99.7m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2019-01-01 to 2019-03-31 | $58.0m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2019-01-01 to 2019-03-31 | $41.7m | us-gaap:GrossProfit |
| Operating income | 3 months2019-01-01 to 2019-03-31 | $6.9m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2019-01-01 to 2019-03-31 | $1.6m | us-gaap:InterestExpense |
| Income tax | 3 months2019-01-01 to 2019-03-31 | $1.4m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2019-01-01 to 2019-03-31 | $3.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2019-01-01 to 2019-03-31 | $0.13 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2019-01-01 to 2019-03-31 | $0.13 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2019-01-01 to 2019-03-31 | 29,579,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2019-01-01 to 2019-03-31 | −$20.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Dividends paid | 3 months2019-01-01 to 2019-03-31 | $581.0k | us-gaap:PaymentsOfDividends |
| Share repurchases | 3 months2019-01-01 to 2019-03-31 | $2.6m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2019-03-31 | $6.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-03-31 | $340.5m | us-gaap:AssetsCurrent |
| Total assets | At period end2019-03-31 | $662.4m | us-gaap:Assets |
| Current liabilities | At period end2019-03-31 | $147.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-03-31 | $333.3m | us-gaap:Liabilities |
| Long-term debt | At period end2019-03-31 | $149.3m | us-gaap:LongTermDebtNoncurrent |
| Short-term borrowings | At period end2019-03-31 | $0 | us-gaap:ShortTermBorrowings |
| Shareholders' equity | At period end2019-03-31 | $329.1m | us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest |
Source: SEC EDGAR, the filing index for accession 0001564590-19-017164. Last ingested by Listed: Nov 11, 2026, 00:16 ET. Listed shows no prices and gives no investment advice.